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Abstract: Micrurus clarki is an uncommon coral snake distributed from the Southeastern Pacific
of Costa Rica to Western Colombia, for which no information on its venom could be found in the
literature. Using a ‘venomics’ approach, proteins of at least nine families were identified, with a
moderate predominance of three-finger toxins (3FTx; 48.2%) over phospholipase A2 (PLA2; 36.5%).
Comparison of this venom profile with those of other Micrurus species suggests that it may represent
a more balanced, ‘intermediate’ type within the dichotomy between 3FTx- and PLA2-predominant
venoms. M. clarki venom was strongly cross-recognized and, accordingly, efficiently neutralized by
an equine therapeutic antivenom against M. nigrocinctus, revealing their high antigenic similarity.
Lethal activity for mice could be reproduced by a PLA2 venom fraction, but, unexpectedly, not by
fractions corresponding to 3FTxs. The most abundant venom component, hereby named clarkitoxin-I,
was identified as a short-chain (type I) 3FTx, devoid of lethal effect in mice, whose target remains to
be defined. Its amino acid sequence of 66 residues shows high similarity with predicted sequences of
venom gland transcripts described for M. fulvius, M. browni, and M. diastema.
Keywords: monadal coral snake; venom; toxin; Micrurus; antivenom; proteome;
Elapidae; neutralization
1. Introduction
Coral snakes (Elapidae) comprise some 71 species that are widely distributed in tropical
and subtropical regions of the New World, from Southeastern USA to Central Argentina [1–3].
Envenomings by these snakes are far less frequent than those inflicted by viperids, but are of medical
concern [4,5].
Micrurus clarki (Figure 1A) is an uncommon, slender to medially robust coral snake with a reported
maximum length of 920 mm, although most adults average between 400 and 600 mm. This species
has a tricolored pattern with narrow yellow bands bordering the black bands followed by single red
bands, and a characteristic black head cap that extends over most of the snout and parietals. M. clarki
has a discontinuous distribution from the Tárcoles basin in Central Pacific Costa Rica southward to
the Pacific lowlands of Western Panamá, where it inhabits lowlands of the Canal Zone, to Pacific
Darien, and Western Colombia. Along this distribution, M. clarki inhabits tropical wet forest, but also
transitional tropical wet-tropical dry forest, where it is mostly found at low elevations, with some
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exceptions reported up to 900 m above sea level [1,6,7]. Little is known about the natural history of this
coral snake. The species was named in honor of H.C. Clark, a medical doctor that directed the Gorgas
Memorial Institute in Panamá, considered a pioneer in tropical medicine [8]. It is considered mainly a
terrestrial and primarily nocturnal species whose natural diet is known to include the marbled swamp




history of  this coral snake. The species was named  in honor of H.C. Clark, a medical doctor  that 
directed the Gorgas Memorial Institute in Panamá, considered a pioneer in tropical medicine [8]. It is 




SDS‐PAGE. Venom was  fractionated on  a C18 RP‐HPLC  column  and  eluted with  an  acetonitrile 
gradient (dashed line) at 1 mL/min. Fractions were further separated by SDS‐PAGE under reducing 











The  venom  of  M.  clarki  (1A)  was  initially  separated  into  33  fractions  by  RP‐HPLC   
(Figure 1B), which were further resolved into 42 protein bands after SDS‐PAGE (Figure 1C). After in‐
gel  tryptic digestion of  these,  followed by MALDI‐TOF‐TOF analysis, protein  family assignments 






Figure 1. (A) Micrurus clarki and (B) separation of its venom (2 mg) by RP-HPLC, followed by (C)
SDS-PAGE. Venom was fractionated on a C18 RP-HPLC column and eluted with an acetonitrile gradient
(dashed line) at 1 mL/min. Fractions were further separated by SDS-PAGE under reducing conditions.
Molecular weight markers (Mw) are indicated in kDa. Coomassie-stained bands were excised, in-gel
digested with trypsin, and subjected to MALDI-TOF/TOF analysis for assignment to protein families,
as shown in Table 1.
Our search of the mainstream literature databases did not find any information on the venom of
M. clarki, whose general characteristics seem to be completely unknown. As part of an ongoing effort
to characterize the venom proteomes of all snake species from Costa Rica [9], in the present work we
report the composition, toxicity, immunological cross-recognition, and neutralization of the venom of
M. clarki obtained from specimens collected in the Southeastern Pacific of this country. In addition, a
three-finger toxin from this venom was isolated and characterized.
2. Results and Discussion
2.1. Proteomic Profile of Micrurus Clarki Venom
The venom of M. clarki (1A) was initially separated into 33 fractions by RP-HPLC (Figure 1B),
which were further resolved into 42 protein bands after SDS-PAGE (Figure 1C). After in-gel tryptic
digestion of these, followed by MALDI-TOF-TOF analysis, protein family assignments were obtained
for 34 of the bands, estimated to represent 95.9% of the total venom proteins. The remaining eight
bands for which no identifications were obtained (indicated as “unknown” in Table 1 and Figure 2),
altogether add to the remaining 4.1% of the venom proteins.
Although not markedly predominant, the protein family with the highest abundance in M. clarki
venom corresponds to three-finger toxins (3FTx), which account for almost half of the protein content
(48.2%), followed by phospholipase A2 (PLA2), representing roughly one-third (36.5%).
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Table 1. Assignment of the RP-HPLC/SDS-PAGE separated fractions of Micrurus clarki venom






Sequence * Conf (%) Sc **
Protein Family; ~ Related
Protein and Species ***m/z z
1 1.3 - - - - - - PNP; adenosine
2–6 1.1 - - - - - - PNP




976.5 1 MFIRTHR 76.6 5 3FTx; ~P01414 , toxin FS-2Dendroaspis polylepis
1322.7 1 ICDDSSIPFLR 99.0 7 3FTx; ~U3EPK7, 3FTx 6Micrurus fulvius




2663.2 1 DGFYSVTCTEKENLCFTMFSAR 99.0 11 3FTx; ~C6JUP4, 3FTx
Micrurus corallinus1375.6 1 ENLCFTMFSAR 99.0 11




1661.8 1 GAYNVCCSTDLCNK 99.0 15 3FTx; ~U3FAE1, 3FTx 3aMicrurus fulvius
1374.7 1 KCLEFIYGGCQ 99.0 12 Kunitz; ~Q6ITB9, mulgin-3Pseudechis australis
13 3.6 9 İ (7071,7201) 1786.9 1 VCYTIFLVGPSYP
pyEK 93.5 6 3FTx; ~AKN63197, 3FTxMicrurus diastema
14 6.9 9 İ (6845)




1310.7 1 AIEFGCAASCPK 99 12 3FTx; ~AKN63198, 3FTxDK, Micrurus diastema
15a 0.4 12 İ - - - - - unknown
15b 2.5 9 İ (6843,7311) 1314.7 1 FYFAYQCTSK man man
3FTx; ~C6JUP1, 3FTx
Micrurus corallinus
16a 0.3 12 İ - - - - - unknown
16b 0.2 10 İ 1373.6 1 CKDFVCNCDR 99.0 7 PLA2; ~U3FYP8, PLA2 13Micrurus fulvius
17a 1.7 13 İ
1373.6 1 CKDFVCNCDR 99.0 14 PLA2; ~U3FYP8, PLA2 13
Micrurus fulvius1085.4 1 DFVCNCDR 96.8 6
17b 1.2 9 İ - - - - - unknown
18 6.6 13 İ (13353)
2969.3 1 HWVSFTNYGCYCGYGGSGTPVDELDK 99.0 12
PLA2; ~P81167, nigroxin B
Micrurus nigrocinctus
1373.5 1 CKDFVCNCDR 99.0 12 PLA2; ~U3FYP8, PLA2 13
Micrurus fulvius
2983.3 1 HWLSFTNYGCYCGYGGSGTPVDELDK 98.5 6
19 11.3 13 İ (13477) 1373.6 1 CKDFVCNCDR 99.0 9 PLA2; ~U3FYN8, PLA2 9Micrurus fulvius
20 1.8 13 İ 2855.3 1 SAWDFTNYGCYCGAGGSGTPVDELDR 99.0 15
PLA2; ~Q8AXW7, PLA2
Micrurus corallinus




99 12 PLA2; ~R4G7M2, Sut-22Suta fasciata
1335.7 1 VHDDCYAAAEK 99 18 PLA2; ~ U3FYP1, PLA2 3bMicrurus fulvius
1827.8 1 CCQVHDNCYNEAEK 99 22 PLA2; ~ A4FS04, natratoxin,Naja atra
22a 2.4 20 İ 1278.6 1 VHDDCYAAAEK 99.0 7 PLA2; ~U3FYP1, PLA2 3bMicrurus fulvius
22b 4.5 13 İ




99.0 15 PLA2; ~Q8AXW7, PLA2Micrurus corallinus






Sequence * Conf (%) Sc **
Protein Family; ~ Related
Protein and Species ***m/z z
23a 0.6 13 İ 1278.5 1 VHDDCYAAAEK 99.0 8 PLA2; ~U3FYP1, PLA2 3bMicrurus fulvius
23b 2.1 11 İ 2883.3 1 PW
kyIGYVNYGCYCGAGG
SGTPVDELDR
99.0 16 PLA2; ~P00606, PLA2Bungarus multicinctus
24 16.1 10 İ (7537)
1478.7 1 RICDDSSIPFLR 99 12 3FTx; ~U3EPK7, 3FTx 10a
Micrurus fulvius1322.6 1 ICDDSSIPFLR 99 15
1108.6 1 KGCASSCPKN 99 13
25 0.9 10 İ 1322.6 1 ICDDSSIPFLR 99.0 9 3FTx; ~U3EPK7, 3FTx 6Micrurus fulvius




27 0.1 - - - - - - unknown
28a 0.2 38 İ
1054.5 1 TYWHYER 99.0 11 MP; ~U3FWL3, MTP4Micrurus fulvius
1130.6 1 EVFDGHTIGR man man MP; ~P85314, MP Bothropsmoojeni
28b 0.2 29 İ 1297.6 1 SAECPTDSFQR 99.0 7 MP: ~R4G7J1, MP-Hop-13Hoplocephalus bungaroides
29a 0.6 38 İ - - - - - unknown
















30c 0.1 29 İ 2171.1 1 GDSGGPLICNGQIQGIVSWGR 99.0 7
SP; ~Q5MCS0, harobin
Hydrophis hardwickii




31a 2.2 61 İ
1637.8 1 NDLEGWHVNLGPMR 99.0 23 LAO; ~U3FYQ2, LAAO 1aMicrurus fulvius
1131.5 1 SDDIFSYER 99.0 13
-1576.9 1 IQDNTENVRVAYRam 99.0 13
1484.7 1 EADYEEFLEIAR 99.0 19
31b 0.5 50 İ
1963.1 1 TSGDIVINDLSLIHQLPK 99.0 7 LAO; ~U3FYQ2, LAAO 1aMicrurus fulvius
2275.1 1 IHFAGEYTANDHGWIDSTIK 99.0 8 -
1484.7 1 EADYEEFLEIAR 99.0 9 -
1310.7 1 RFDEIVGGM˝xDR 99.0 10 LAO; ~A0A0A1WCY6, Bvariant Echis coloratus
1460.8 1 QVVPESLFAWER 95.0 7 PLB: ~V8ND68, PLB-like 1Ophiophagus hannah
31c 1.1 42 İ
1484.7 1 EADYEEFLEIAR 99.0 13
LAO; ~U3FYQ2, LAAO 1a
Micrurus fulvius
1963.0 1 TSGDIVINDLSLIHQLPK 99.0 17
2275.0 1 IHFAGEYTANDHGWIDSTIK 99.0 20
1131.5 1 SDDIFSYER 99.0 11
1576.8 1 IQDNTENVRVAYRam 99.0 12
31d 0.7 20 İ - - - - - unknown






Sequence * Conf (%) Sc **
Protein Family; ~ Related
Protein and Species ***m/z z
31e 0.2 17 İ
1589.8 1 NDLEGWHVNLGPMdtR 99.0 9
LAO; ~U3FYQ2, LAAO 1a
Micrurus fulvius
1466.7 1 EpyADYEEFLEIAR 99.0 11
1833.8 1 EFVQEDENAWYYIK 99.0 19
1637.8 1 NDLEGWHVNLGPMR 99.0 12
1484.7 1 EADYEEFLEIAR 99.0 17
31f 0.4 14 İ - - - - - unknown
32 0.9 23 İ 1152.6 1 LPFYADWIK 99.0 12 SP; ~U3FBP8, prostasin-likeprotein Micrurus fulvius
İ reduced SDS-PAGE apparent mass, in kDa. Selected peaks were analyzed by mass spectrometry, and their
masses (Da) are shown in parentheses; * Cysteine residues are carbamidomethylated. Possible, although
unconfirmed/ambiguous amino acid modifications, suggested by the automated identification software are
shown in superscript, with the following abbreviations: ox: oxidized; da: deamidated; py: pyroglutamic;
fo: formyl; dh: dehydrated; am: amidated; ky: hydroxykynurenin; dt: dethiomethyl; ** Confidence (Conf)
and score (Sc) values are calculated by the Paragon® algorithm of ProteinPilot® v.4.0. Few spectra that
were manually resolved are indicated by “man’‘; *** Abbreviations: PNP: peptide or non-proteic; 3FTx:
three-finger toxin; PLA2: phospholipase A2; Kunitz: Kunitz-type serine proteinase inhibitor; CTL: C-type
lectin/lectin-like; MP: metalloproteinase; SP: serine proteinase; LAO: L-amino acid oxidase; PLB: phospholibase
B; GPX: glutathione peroxidase.
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acid  oxidase;  CTL:  C‐type  lectin/lectin‐like;  MP:  metalloproteinase,  SP:  serine  proteinase;   
KUN: Kunitz‐type serine proteinase inhibitor; GPX: Glutathione peroxidase; PLB: phospholipase B; 
PNP: peptides and/or non‐proteinaceous components; UNK: unknown/unidentified. 
In  addition  to  its  abundant  3FTxs  and PLA2s,  other  proteins detected  in  lower  proportions 
(within  the  range  of  0.9%–3.8%)  belong  to  the  L‐amino  acid  oxidase, metalloproteinase,  serine 





The most  intense  of  these  initial peaks  (1–3) were  analyzed  by nESI‐MS,  and  clear  evidence  for 
adenosine being present  in peak 1 was obtained  (Figure 3). Adenosine has been  found  in several 
venoms from Micrurus species, although not ubiquitously [10,11], and may have a contributing role 
in envenoming strategies [12], a hypothesis which still remains to be studied in detail. 
Fig re 2. o ositio of icrurus clarki venom proteome according to protein families, expressed
as percentages of the total protein content. 3FTx: three-finger toxin; PLA2: phospholipase A2; LAO:
L-amino acid oxidase; TL: C-type lectin/lectin-like; MP: metalloproteinase, SP: serine proteinase;
K : Kunitz-type serine proteinase inhibitor; GPX: Glutathione peroxidase; PLB: phospholipase B;
PNP: peptides and/or non-proteinaceous co ponents; UNK: unknown/unidentified.
I addition to its abundant 3FTxs and PLA2s, other proteins detected in lower proportions (within
the ra ge of 0.9%–3.8%) belong to the L-amino acid oxidase, metalloproteinase, serine proteinase,
Kunitz-type serine proteinase inhibitor, and C-type lectin/lectin-like families, together with traces
(~0.2%) of phospholipase B and glutathion peroxidase components (Figure 2). Altogether, proteins in
this venom belong to at least nine families. As expected, the rapidly eluting peaks in the RP-HPLC
separation of the ve m (Figure 1B; peaks 1–6), did not show proteins by electrophoresis, and are
considered to contain either small peptides or non-pr teinaceous comp nds (PNP; 2.4%). The most
intense of these initial peaks (1–3) were analyzed by nESI-MS, a d clear evi ence for a e osine
being present in peak 1 was obtained (Figure 3). Adenosine has been found in several venoms from
Micrurus species, although not ubiquitously [10,11], and may have a contributing role i envenoming
strategies [12], a hypothesis whic still remains to be studied in detail.
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Figure 3. Detection of adenosine in Micrurus clarki venom by nESI-MS/MS. (A) Fraction 1 from Figure 1
was directly infused into the nano-spray ion source of a QTrap 3200 mass spectrometrer, and scanned
in positive enhanced MS mode; and (B) the ion labeled at m/z 268.2 (dotted red circle in A) was selected
for collision-induced dissociation, showing the characteristic fragment of m/z 136.1, which corresponds
to the transition of adenosine to adenine.
2.2. Immunological Properties of Micrurus Clarki Venom
Since the antivenom used therapeutically for coral snake envenomings in Central America
(SAC-ICP) is prepared by immunization of horses with the venom of a single species, M. nigrocinctus,
it was of interest to characterize its immunological cross-recognition and cross-neutralization toward
the untested venom of M. clarki. As shown by ELISA titration curves, this antivenom strongly
cross-recognized M. clarki whole venom, resulting in antibody binding signals virtually as high as
those obtained for the homologous (M. nigrocinctus) venom (Figure 4). This finding evidences the high
degree of antigenic conservation between venoms of these two coral snake species. Following this
result, a more detailed cross-recognition analysis was performed using the RP-HPLC-separated venom
fractions of M. clarki, revealing additional information. First, it evidenced that the antivenom contains
antibodies against all of the venom fractions tested, since the binding signals recorded were, in all cases,
significantly higher than those of the negative control equine immunoglobulins (Figure 5). Second, it
showed that immunorecognition of smaller proteins, such as 3FTxs or Kunitz-type components, is
generally weaker in comparison to recognition of the larger PLA2s or LAAOs (Figure 5). The lower
titers of antibodies against low molecular mass proteins may reflect differences in their immunogenicity,
and/or epitope availability in the immunoassay, and is in agreement with earlier studies performed
with other Micrurus venoms [13,14] or with venoms from other elapids [15,16].
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Figure  5.  Immunorecognition  of  the  RP‐HPLC  fractions  of Micrurus  clarki  venom  by  an  equine 
monospecific antivenom  raised against M. nigrocinctus venom  (SAC‐ICP), as evaluated by ELISA. 
Venom  fractions  (0.4  g/well) were  coated  onto microplates,  and  the  binding  of  antibodies was 
detected  as  described  in  Methods,  using  anti‐equine  immunoglobulins  conjugated  to  alkaline 









SAC‐ICP  antivenom  should  be  capable  of  efficiently  cross‐neutralizing  its  toxicity.  Since  no 
information was available on the lethal potency of this venom, experiments were first performed to 
estimate  this  value,  indicating  an  intravenous median  lethal  dose  (LD50)  of  12.4  g/mouse  (95% 
confidence limits of 7.1–23.5 g/mouse) or 0.73 g/g body weight (0.42–1.38 g/g). Using 4 × LD50 of 
venom (50 g) as a challenge, the SAC‐ICP antivenom indeed protected all mice from intravenous 
Figure 4. Cross-recognition of the venom of Micrurus clarki by an equine antivenom raised against
M. nigrocinctus venom (SAC-ICP), as evaluated by ELISA. Crude venom fro each of the t o species
as coated onto microplates at 1 µg/ ell, as described in ethods. Serial dilutions of the antiveno
ere added and the binding of antibodies was detected by anti-equine im unoglobulins conjugated to
alkaline phosphatase, followed by color development using p-nitrophenylphosphate substrate. A mock
antivenom prepared using the plasma of a normal, n-immunized horse, was used as a negative
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estimate  this  value,  indicating  an  intravenous median  lethal  dose  (LD50)  of  12.4  g/mouse  (95% 
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Figure 5. I r c iti f t - fr cti s f icr r s clarki a equine
s ecific a ti e r ise i st . i roci ct s e ( -I ), s e l te I .
enom fractions (0.4 µg/well) were coated onto microplates, nd the binding of antibodies was etected
as described in Methods, using anti-equi e immunoglobulins conjugated to alkaline phosphatase,
foll wed by color dev lopment using p-nitrophenylphosphate substrate. Mock ntivenom prepared
using the plasma of a normal, non-immunized horse, was used as a negative control for background.
Each bar represents mean ˘ SD of triplicate w lls. All bars corresponding to SAC-ICP have values
that are significantly higher (p < 0.05; Student’s t-test) than controls. Colored circles above the bars
indicate the protein family identified in each chroma ographic fra tion: three-finger tox n (3FTx),
unknown (Unk), phospholipase A2 (PLA2), L-amino acid oxidase (LAO), and Kunitz-type seri e
protease inhibitor (Kun). The black circle repres nts the c ude venom (V) control.
2.3. et al ctivity of icr r s larki eno and its eutralization by Antivenom
I orecognition results obtained for . clarki veno or its ai fracti s re icte t at t e
S -ICP antivenom should be capable of efficiently ross-neutralizing its toxicity. Since no information
was available on the lethal potency of this v om, experiments wer first performed to estimate this
value, indicating an intravenous median lethal dose (LD50) of 12.4 µg/mouse (95% confidence limits
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of 7.1–23.5 µg/mouse) or 0.73 µg/g body weight (0.42–1.38 µg/g). Using 4 ˆ LD50 of venom (50 µg)
as a challenge, the SAC-ICP antivenom indeed protected all mice from intravenous lethality when
preincubated with the venom at all ratios tested (100, 200, 300, and 400 µg venom/mL antivenom).
Due to the low amounts of venom available, we could not test neutralization beyond the 400 µg/mL
ratio in order to estimate the median Effective Dose (ED50). Nevertheless, these results indicate that
the neutralization potency of SAC-ICP against the lethal action of M. clarki venom is at least as high
as that against the homologous (M. nigrocinctus) venom (unpublished data from the Quality Control
Lab of Instituto Clodomiro Picado), in agreement with the immunological cross-recognition results
(Figures 4 and 5).
2.4. Phospholipase A2 and Myotoxic Activities of Micrurus Clarki Venom
The venom of M. clarki showed PLA2 activity upon the synthetic substrate NOBA (Figure 6A), in
agreement with the presence of proteins, identified as PLA2s in its composition (Figure 2 and Table 1).
In comparison to the venom of M. nigrocinctus, that of M. clarki presents a lower activity (Figure 6).
This finding correlates well with the proportion of PLA2 enzymes found in the two venoms: 48.0% in
M. nigrocinctus [13], and 36.5% in M. clarki (Figure 2).
On the other hand, the venom of M. clarki displayed a significant myotoxic activity in mice
(Figure 6B). This effect was evidently less potent in comparison to that of M. nigrocinctus venom, under
identical assay conditions (Figure 6B). This observation is also in line with the differences in PLA2
content in the venoms of these two species, since the myotoxicity induced by Micrurus venom has
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On  the other hand,  the venom of M.  clarki displayed a  significant myotoxic activity  in mice 







Methods. Each point  represents mean  ±  SD  of  triplicate  assays;  and  (B) myotoxic  activity  of  the 
venoms of M. clarki and M. nigrocinctus in mice. Venoms (5 g/50 L) or phosphate‐buffered saline 
(PBS,  50  L) were  injected  by  intramuscular  route  and  the  plasma  creatine  kinase  activity was 
determined 3 h later. Each bar represents mean ± SD of four mice per group. 
  
Figure 6. (A) Phospholipase A2 activity of the veno s of icrurus clarki and M. nigrocinctus upon the
monodisperse synthetic substrate 4-nitro-3-octanoyloxy-benzoic acid, under conditions described in
Methods. Each point represents mean˘ SD of triplicate assays; and (B) myotoxic activity of the venoms
of M. clarki and M. nigrocinctus in mice. Venoms (5 µg/50 µL) or phosphate-buffered saline (PBS, 50 µL)
were injected by intramuscular route and the plasma creatine kinase activity was determined 3 h later.
Each bar represents mean ˘ SD of four mice per group.
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2.5. Lethality Screening of Micrurus Clarki Venom Fractions in Mice
Aiming to identify which of the venom proteins M. clarki contribute to its lethal effect in mice,
and, therefore, predict their potential relevance to human envenomings, screenings were performed
with its most abundant RP-HPLC fractions, using a challenge of 10 µg/mouse by the intravenous
route. Intriguingly, fractions 7, 8, 10, 13, 14, 15, 24 (corresponding to 3FTxs), 12 (containing a 3FTx and
a Kunitz-type protein), 18, or 19 (corresponding to PLA2s) did not induce lethality in this screening.
Of all fractions tested, only fraction 21, corresponding to a PLA2, was individually lethal to mice. This
finding is surprising, since many 3FTxs in snake venoms act as post-synaptic blockers of nicotinic
acetylcholine receptors at the neuromuscular junction of mammals and/or birds, therefore being
endowed with potent lethal effect [17–19]. The possible loss of activity by the compact, disulfide-rich
3FTxs, due to exposure to acidic acetonitrile gradients during their RP-HPLC separation seems unlikely,
since a previous study showed that such procedure did not reduce the lethal potency of Dendroaspis
polylepis (Elapidae) venom, in which 3FTxs play a predominant role [15]. Therefore, it is puzzling
that lethality was observed only in a single (PLA2) fraction of the chromatographic profile of M. clarki
venom, and in none of the 3FTx fractions. This finding is suggestive of possible synergisms among
different venom components to induce lethality. However, the evaluation of this possibility requires
more detailed studies, which could not be performed due to the scarcity of venom.
2.6. Characterization of Clarkitoxin-I
Of particular interest was the most abundant venom component, peak 24, representing 16.1%
of the total proteins, which was identified as a member of the 3FTx family (Table 1) but was devoid
of lethal effect in mice. By performing an in-solution trypsin digestion and MALDI-TOF-TOF de
novo sequencing of RP-HPLC-separated peptides, the complete amino acid sequence of this protein,
hereby named clarkitoxin-I, was determined (Figure 7A). Despite the fact that this protein is not toxic
in mice, we have coined the name ‘clarkitoxin’ because it belongs to the family of the 3FTxs, and
because it might be toxic for other species, particularly natural prey species [20]. Its C-terminal four
residues (DNCI) were not directly observed in the analysis of tryptic peptides, but their presence is
deduced on the basis of (a) matching the isotope-averaged mass (Mav) observed for the intact protein
of 7537 ˘ 1 Da (Figure 7B) with its theoretically-expected Mav of 7536 Da, according to this sequence;
and (b) the absolute conservation of the DNCI sequence in four highly similar deduced sequences of
venom gland transcripts or cDNAs from M. browni (AKO63246, AKO63245), M. diastema (AKN63202),
and M. fulvius (U3EPK7) (Figure 7C). The protein sequence data reported in this paper will appear in
the UniProt Knowledgebase under the accession number C0HK04. Clarkitoxin-I presents 66 amino
acid residues, with the conserved pattern of eight cysteine positions and spacings that identifies it as
a short-chain (type I) 3FTx, and is indeed identical to the sequence predicted by transcript U3EPK7
(cluster 10) sequenced from the venom gland transcriptome of M. fulvius [21], which however has not
been isolated and characterized at the protein level. Three homologous sequences from M. browni
and M. diastema present identities of 95%–97% in comparison to clarkitoxin-I (Figure 7C), but the
next most similar protein retrieved in a BLAST search, F5CPD3 from M. altirostris, drops abruptly
to a value of 50% identity. This large gap in similarity suggests that clarkitoxin-I, together with the
closely-related variants described in M. fulvius, M. diastema, and M. browni, may form a group that
should be phylogenetically distant from other proteins of the elapid 3FTx family, and most likely of
uncharacterized functional properties (owing to the scarcity of Micrurus venoms).
Clarkitoxin-I was not lethal when injected by the intravenous route at 10 µg/mouse, and even
the intraperitoneal injection of 30 µg into a single mouse did not cause death or evident abnormal
signs. Therefore, this 3FTx protein can be considered to be devoid of significant α-neurotoxicity in
mice. Toxicity to other groups of organisms such as small colubrids or swamp eels, being natural prey
for coral snakes [6], was not tested and, thus, remains an open possibility. In this regard, a rational
explanation for the prominent abundance of this protein in M. clarki venom cannot yet be proposed.
Determination of the precise target specificity of this 3FTx is a pending task, which will require an
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adequate source of protein, such as recombinant or synthetic, due to the difficulties of obtaining venom
from this coral snake species.
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Figure 7. Biochemical characterization of clarkitoxin-I, a three-finger toxin isolated from the venom
of Micrurus clarki. (A) Amino acid sequence of clarkitoxin-I, as determined by MALDI-TOF/TOF of
tryptic peptides. The protein corresponds to peak 24 of the RP-HPLC separation of venom presented
in Figure 1. De novo-derived sequences from the peptides and their observed monoisotopic masses are
indicated below the assembled sequence. Cysteine residues (red) were carboxamidomethylated. Few
residues additionally carboxamidomethylated in the tryptic digests are underlined, and asparagine
residues that showed deamidation are indicated by italics. The C-terminal four residues (DNCI) were
not observed in the analysis of tryptic peptides, but their presence is deduced on the basis of matching
the isotope-averaged mass observed for the intact protein (B) and the theoretically calculated mass.
Moreover, these four amino acids at the C-terminal region are conserved in the alignment of clarkitoxin-I
with four homologous deduced proteins (C) reported in venom gland transcripts of M. fulvius, M. browni,
and M. diastema. Amino acid positions that differ in comparison to clarkitoxin are highlighted in green,
and sequence identity values are shown at the right (Id%). The sequence here reported for clarkitoxin-I
will appear in the UniProt Knowledgebase under the accession number C0HK04.
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2.7. Dichotomy of Venom Types in Micrurus and the Position of Micrurus Clarki
The increasing proteomic data on Micrurus venoms have revealed a dichotomy between 3FTx-
and PLA2-predominant types, which shows a correlation with phylogenetic relationships among the
taxa [15]. In this regard, by containing a moderately higher proportion of 3FTxs than PLA2s, the
venom of M. clarki could be grouped together with 3FTx-rich venoms such as those of M. altirostris, M.
corallinus, M. mipartitus, M. multifasciatus, and M. alleni [15,22,23]. However, it should be noted that in
the venoms of these latter coral snakes, 3FTxs represent a considerably higher proportion of the total
proteins (61.1%–83.0%), and their relative PLA2 content, consequently, is markedly lower (8.2%–29.0%).
Considering that the predominance of 3FTxs over PLA2s (48.2% vs. 36.5%, respectively) is less
pronounced in the venom of M. clarki, its compositional pattern appears to differ from the markedly
3FTx-predominant Micrurus venoms described to date, and seems to represent a more ‘intermediate’
pattern. In fact, some functional and immunological characteristics of M. clarki venom show similarities
with those observed in the group of PLA2-rich venoms. For example, Micrurus venoms from Costa Rica,
which present the 3FTx-predominant expression pattern, have been found to diverge antigenically from
the (PLA2-predominant) venom of M. nigrocinctus, used for the production of therapeutic antivenom
in the region. As a consequence, they are weakly neutralized (M. alleni) or not neutralized at all
(M. mipartitus/M. multifasciatus) by this antivenom [15,23]. In contrast, the present study shows
that the venom of M. clarki clearly departs from this trend, by presenting a strong immunological
cross-reactivity with the venom of M. nigrocinctus, which leads to an excellent cross-neutralization by
its antivenom. An additional difference between M. clarki venom and 3FTx-predominant venoms, e.g.,
M. mipartitus from Colombia, can be pointed out from the present findings. The latter contains a highly
abundant (28%) 3FTx, mipartoxin-I, which is potently lethal to mice [23,24], whereas the most abundant
protein in M. clarki venom, clarkitoxin-I (16%), is hereby characterized as a 3FTx that lacks a lethal effect
in mice. Additionally, the venom of M. clarki showed a considerable myotoxic effect in mice, in contrast
with the 3FTx-rich venoms of M. alleni [11] or M. mipartitus [23], which do not display significant
myotoxicity. Moreover, the amino acid sequence of clarkitoxin-I, its most abundant component, reveals
a high conservation (95%–100% identity) in at least three other Micrurus species (M. diastema, M. browni,
and M. fulvius) from the North American clade, displaying a PLA2-predominant pattern [15,25,26].
Although a definitive phylogenetic hypothesis for the species included in the genus Micrurus is still
pending, a preliminary analysis of the phylogenetic positions of monadal coral snakes of Middle
America based on two mitochondrial genes [27] has shown a close relationship between M. clarki and
the M. nigrocinctus-M. fulvius clade. Altogether, the present results portray the venom of M. clarki as
being only moderately 3FTx-predominant, displaying a more intermediate pattern between the two
poles of the 3FTx/PLA2 dichotomy, and sharing several functional and antigenic characteristics with
the PLA2-predominant Micrurus venoms.
3. Conclusions
To the best of our knowledge, the venom of M. clarki is studied here for the first time, by presenting
its proteomics-based compositional profile, toxicity, and immunological recognition/neutralization
properties. Protein composition indicates that this venom contains a higher proportion of 3FTxs
over PLA2s, however not with a predominance as marked as in other coral snake venoms previously
described to express the ‘3FTx-rich’ pattern. To further investigate the relationship between phylogeny
and venom composition in New World elapids [15] it will be of importance to increase the number
of Micrurus venoms characterized by means of a venomics approach, since only a minor fraction of
the nearly 70 coral snake species distributed in America have had such type of analysis performed.
The present study completes the venom proteomic profiling of all five coral snake species reported
in Costa Rica, namely M. nigrocinctus, M. mosquitensis, M. alleni, M. multifasciatus (also described as
M. mipartitus), and M. clarki, revealing a remarkable diversity in their protein composition, toxicity,
and antigenic properties.
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4. Experimental Section
4.1. Venom and Antivenom
Venom was obtained from three M. clarki adult specimens, all collected in localities of the
Southeastern Pacific region of Costa Rica (ICP-078 Punta Mala, Puerto Cortés, Puntarenas, Costa
Rica; ICP-079 Lagunas, Aguirre, Puntarenas, Costa Rica; and ICP-806 Platanillo, Pérez Zeledón, San
José, Costa Rica) and kept at the Serpentarium of Instituto Clodomiro Picado, University of Costa Rica.
Venom samples were pooled, lyophilized, and stored at ´20 ˝C until analysis. A total of ~15 mg of
venom was obtained. For the purpose of studying immunological cross-recognition and neutralization
of this venom, the monospecific equine anti-coral snake antivenom against M. nigrocinctus, produced
at Instituto Clodomiro Picado (SAC-ICP; batch 520, expiry date March 2016) was used.
4.2. Proteomic Profiling of the Venom
The “snake venomics” analytical strategy [28] was followed, as previously described [29]. In brief,
the venom was decomplexated by a RP-HPLC step, followed by SDS-PAGE of each of the obtained
fractions. Protein bands were excised and in-gel digested with trypsin after reduction and alkylation.
The obtained peptides were submitted to MALDI-TOF/TOF mass spectrometry on a Proteomics
Analyzer 4800 Plus (Applied Biosystems, Foster City, CA, USA) instrument for assignment to known
protein families by similarity with sequences contained in the UniProt/SwissProt database (Serpentes,
January 2016), using the ProteinPilot® software (ProteinPilot Software v.4.0, 2010) and the Paragon®
algorithm (ABsciex, Redwood City, CA, USA), at a confidence level of ě95%.
4.3. Quantitative Estimation of the Protein Family Composition of the Venom
The relative abundance of each protein (% of total venom proteins; [29]) was estimated by
integration of the RP-HPLC peak signals at 215 nm, using Chem Station® B.04.01 software (Agilent,
Santa Clara, CA, USA, 2009). For HPLC peaks presenting more than one SDS-PAGE band, percentage
distribution was assigned by densitometry, using a ChemiDoc® recorder and Image Lab® v.2.0 software
(Bio-Rad, Hercules, CA, USA).
4.4. Immunological Cross-Recognition of Venom and its RP-HPLC Fractions
The ability of equine antivenom raised against M. nigrocinctus venom (SAC-ICP) to cross-recognize
whole M. clarki venom, or its RP-HPLC fractions, was assessed by ELISA [14]. Crude venoms of
M. clarki and M. nigrocinctus were dissolved in 0.1 M Tris, 0.15 M NaCl, pH 9.0 buffer, and coated
onto microplates (Nunc) at 1 µg/100 µL/well, overnight at 4 ˝C. Plates were washed five times with
PBS (0.12 M NaCl, 40 mM sodium phosphate, pH 7.2), blocked for 60 min with 100 µL/well of PBS
containing 2% bovine serum albumin (BSA), and decanted. Then, 100 µL of antivenom (serially diluted
from 1:500 to 1:64,000) were added and incubated for 2 h. An identical preparation of immunoglobulins
obtained from a non-immunized horse was used as a negative control. Plates were washed five times
with PBS, followed by the addition of 100 µL of anti-equine immunoglobulins-alkaline phosphatase
conjugate (Sigma), diluted 1:4000 in PBS-BSA, and incubated for 2 h. After five washings with
PBS, color was developed with 1 mg/mL p-nitrophenylphosphate in diethanolamine buffer, pH 9.8,
and absorbances were recorded at 405 nm. All samples were assayed in triplicate wells. A similar
ELISA procedure was used to assess the recognition of RP-HPLC fractions of M. clarki venom by the
SAC-ICP antivenom. In this case, microplates were coated with 0.4 µg/100 µL/well of each fraction
and the binding of equine antibodies was tested at an antivenom dilution of 1:1000, in PBS-BSA, as
described above.
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4.5. Mass Determination of Clarkitoxin-I by Electrospray Mass Spectrometry
The protein from peak 24 (2 µg) of the RP-HPLC separation of M. clarki venom was diluted in
10 µL of 50% acetonitrile containing 0.1% formic acid, and loaded into a metal-coated glass capillary
(Proxeon) for direct infusion into a QTrap3200 mass spectrometer (Applied Biosystems, Foster City,
CA, USA) using a nano-electrospray ionization source operating at 1200 V. The sample was analyzed
in the positive enhanced multi-charge mode, and the ion series was deconvoluted with the aid of
the Analyst v.1.5 software (ABsciex, Redwood City, CA, USA, 2008) to obtain the isotope-averaged
molecular mass (Mav) of the protein.
4.6. Amino Acid Sequencing of Clarkitoxin-I by Tandem Mass Spectrometry
The protein from peak 24 (75 µg) of the RP-HPLC separation of M. clarki venom was dissolved
in ammonium bicarbonate (50 mM), reduced with dithiothreitol (10 mM) for 30 min at 56 ˝C, and
alkylated with iodacetamide (50 mM) for 20 min in the dark. Sequencing grade trypsin (1.5 µg) was
added and incubated for 18 h at 37˝C. The resulting peptide mixture was separated by RP-HPLC on a
C18 column (2.1 ˆ 150 mm, 5 µm particle diameter) eluted at 300 µL/min with a gradient from 0.1%
trifluoroacetic acid (TFA) in water (solvent A) to acetonitrile/0.1% TFA (solvent B) as follows: 10 min
at 0% B, 5 min to 12% B, 30 min to 30% B, 5 min to 70% B, and 10 min at 70% B. Peptides were collected
manually, dried by vacuum centrifugation, and redissolved in 20 µL of 50% acetonitrile containing
0.1% TFA, followed by MALDI-TOF/TOF analysis as previously described [29].
4.7. Venom Lethality and its Neutralization by Antivenom
Venom was dissolved in PBS, and various doses were injected by the intravenous route into
groups of four CD-1 mice of 16–18 g of body weight, of either sex. Deaths occurring during the next
48 h were recorded and the median lethal dose (LD50) for the venom was calculated by probits [30].
The ability of the equine antivenom against M. nigrocinctus (SAC-ICP) to neutralize the lethal
activity of M. clarki venom was assessed by a preincubation-type approach. Groups of four mice
(16–18 g) were injected intravenously with 100 µL of a solution that contained 50 µg of venom
(equivalent to 4 ˆ LD50), which had been previously mixed and incubated for 30 min at 37 ˝C with
antivenom in order to attain various venom/antivenom ratios: 100, 200, 300, and 400 µg of venom/mL
of antivenom. A control group of mice received the same dose of venom, incubated with PBS instead
of antivenom. Deaths occurring during the following 48 h were recorded in each group. All in vivo
assays followed guidelines by the Institutional Committee on the Use and Care of Laboratory Animals
(CICUA) at the University of Costa Rica (CICUA 041-15, 21 October 2015).
4.8. Phospholipase A2 and Myotoxic Activities of Micrurus Clarki Venom
The PLA2 activity of M. clarki venom was tested on the monodisperse synthetic substrate
4-nitro-3-octanoyloxy-benzoic acid (4-NOBA) as described [14]. Variable amounts of venoms (in
25 µL of 10 mM Tris, 10 mM CaCl2, 100 mM NaCl, pH 8.0 buffer) were added to microplate wells (in
triplicates), mixed with 25 µL of substrate (1 mg/mL in acetonitrile) and 250 µL of the same buffer.
After incubation for 60 min at 37 ˝C, absorbances were recorded at 405 nm in a microplate reader and
activity was expressed as the absorbance change in comparison to the substrate alone. For comparative
purposes, the venom of M. nigrocinctus was run in parallel in this assay, under identical conditions.
The myotoxic activity of M. clarki venom was tested in mice (n = 4), which received an
intramuscular injection of 5 µg in the gastrocnemius, in a volume of 50 µL of PBS. A control group of
mice received only PBS. The venom of M. nigrocinctus was injected in another group of mice, under
identical conditions, for comparison. Three hours after injection, all animals were bled from the tip of
the tail, and the activity of creatine kinase in their plasma was determined using a UV kinetic-based
enzymatic assay (CK-Nac, Biocon, Brea, CA, USA), as described [14].
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4.9. Lethality Screening of Venom Fractions
The main venom fractions obtained by the RP-HPLC separation were screened for lethal activity
in mice, by injecting 10 µg/100 µL by the intravenous route and recording deaths up to 48 h, using
two mice per fraction. In addition, clarkitoxin-I was injected at a dose of 30 µg in one mouse, by the
intraperitoneal route.
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